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Abstract
Background: High levels of A in the cerebral cortex dis-
tinguish demented Alzheimer’s disease (AD) from nonde-
mented elderly individuals, suggesting that decreased
amyloid-beta (A) peptide clearance from the brain is a
key precipitating factor in AD.
Materials and Methods: The levels of A in brain and
plasma as well as apolipoprotein E (ApoE) in brain were
investigated by enzyme-linked immunosorbent assay
(ELISA) and Western blotting at various times during the
life span of the APP23 transgenic (Tg) and control mice.
Histochemistry and immunocytochemistry were used to
assess the morphologic characteristics of the brain paren-
chymal and cerebrovascular amyloid deposits and the
intracellular amyloid precursor protein (APP) deposits in
the APP23 Tg mice. 
Results: No significant differences were found in the
plasma levels of A between the APP23 Tg and control mice
from 2–20 months of age. In contrast, soluble A levels 
in the brain were continually elevated, increasing 4-fold at
2 months and 33-fold in the APP23 Tg mice at 20 months
of age when compared to the control mice. Soluble A42
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was about 60% higher than A40. In the APP23 Tg mice,
insoluble A40 remained at basal levels in the brain until
9 months and then rose to 680 g/g cortex by 20 months.
Insoluble A40 was negligible in non-Tg mice at all ages.
Insoluble A42 in APP23 Tg mice rose to 60 g/g cortex at
20 months, representing 24 times the control A42 levels.
Elevated levels of ApoE in the brain were observed in the
APP23 Tg mice at 2 months of age, becoming substantially
higher by 20 months. ApoE colocalized with A in the
plaques. Beta-amyloid precursor protein (APP) deposits
were detected within the neuronal cytoplasm from 4 months
of age onward. Amyloid angiopathy in the APP23 Tg mice
increased markedly with age, being by far more severe
than in the Tg2576 mice. 
Conclusions: We suggest that the APP23 Tg mouse may
develop an earlier blockage in A clearance than the
Tg2576 mice, resulting in a more severe accumulation of
A in the perivascular drainage pathways and in the
brain. Both Tg mice reflect decreased A elimination and
as models for the amyloid cascade they are useful to study
AD pathophysiology and therapy.
Introduction
Alzheimer’s disease (AD) has a multifactorial patho-
genesis in which one of the major features is the de-
position of amyloid-beta (A) peptides as plaques
in brain parenchyma and in vessel walls as cerebral
amyloid angiopathy (CAA). Despite the prominence
of insoluble deposits of A in the AD brains, recent
observations suggest that these brains can be distin-
guished from those of nondemented elderly, not only
by the amount of insoluble A in plaques in the
brain but also by the high levels of soluble A (1,2).
This suggests that failure of soluble A to clear from
the extracellular space of the cortex may play a ma-
jor role in the induction of dementia in AD. The ques-
tions therefore arising are: how does A normally
drain from the brain, how is this drainage impeded,
and how can drainage of A be improved?
Tracer studies and physiologic experiments in
rodents have shown that drainage of interstitial fluid
and proteins from the extracellular space of the brain
depends on (1) the size and charge of the molecules,
(2) the dimensions of the extracellular space of the
cortex, and (3) the presence of flow channels around
capillaries and arteries (3–6). The pattern of distrib-
ution of a number of different amyloids such as A
(7), cystatin (8), PrP (9), and ABri (10,11) in their
respective cerebral amyloid angiopathies suggests
that amyloid peptides are deposited in perivascular
drainage pathways, both within the cortex and in the
leptomeninges (12). Defining the biochemical factors
and physiologic influences that govern drainage of
all these amyloid peptides from the human brain
will offer therapeutic opportunities for the reduc-
tion in amyloid load in the brain and thus possibly
amelioration of the clinical features of AD and other
dementias.
The development of beta-amyloid precursor pro-
tein (APP) transgenic (Tg) mice carrying mutations
that enhance the production of the A peptides has
opened new avenues for testing the hypothesis that
failure of perivascular drainage of A is a major
event in the pathogenesis of AD. In this dementia,
the amount of insoluble A n-40 and A n-42 accu-
mulating in the brain parenchyma and cerebrovas-
cular walls appears to be intimately correlated with
the apolipoprotein E (ApoE) genotype. In the brain,
ApoE plays a major role in the transport of choles-
terol and triglycerides, and in the transport and clear-
ance of A peptides, and is synthesized by astroglial
and microglial cells. In humans there are three al-
lelic forms of ApoE recognized as 2, 3, and 4, which
code for three ApoE polypeptides: ApoE2, ApoE3,
and ApoE4. There is a definitive association between
the number of copies an individual has of the ApoE4
form and the risk of developing early-onset AD as
well as between ApoE4 and the CAA in AD. Those
carrying the ApoE 4/4 genotype have an over-
whelming amount of amyloid deposited in the brain
parenchyma and in cortical and leptomeningeal ves-
sel walls.
The APP Tg mice also provide an opportunity
for tracking amyloid deposition and drainage. Thus,
throughout the life span of these rodents, the level of
water-soluble and water-insoluble A peptides and
ApoE can be measured in the brain and correlated
with levels of soluble A in the plasma. From a
chemical viewpoint, the A peptides can be struc-
turally analyzed and equated with the type of amy-
loid deposits observed morphologically. Further-
more, the differences between strains of Tg mice can
be determined, thus offering different facets of the
spectrum of amyloid deposition and drainage. Most
importantly, however, the Tg animal models would
be ideal for assessing the efficacy of drugs or anti-
bodies destined to increase clearance of A, reduce
the amyloid burden, and enhance cognitive ability.
The present study compares levels of A in
blood and brain throughout the life span of APP23
Tg mice. In this strain, the APP gene expression is
driven by the neuronal Thy-1 promoter. Amyloid
deposition is first visible microscopically in the
brain parenchyma and in arterial walls as CAA at
about 7–9 months of age (13). A levels in the brain
and plasma are compared between APP23 Tg and
control mice from 2–20 months of age. Because the
age of onset of sporadic AD and the metabolism of
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A appear to be intimately associated with ApoE
(14), we also determined the levels of ApoE in the
mouse brain tissue. Finally, the pattern of A accu-
mulation in the brain in APP23 Tg mice is com-
pared to that of another strain of APP Tg mouse, the
Tg2576, that we characterized previously (15). We hy-
pothesize that a progressive failure in the clearance
of A from the brain to the blood in the APP 23 Tg
mice results in the characteristic accumulation pat-




The levels of A40 and A42 were estimated in the
blood and in the brains of the APP23 Tg mice and
in non-Tg control mice. In the brain, the A pep-
tides were quantified in the water-soluble and wa-
ter-insoluble tissue fractions. A total of 72 mice
were used in these experiments: 36 were Tg for the
human APP751 carrying the Swedish mutations
(K670N and M671L) under the neuronal murine
Thy-1 promoter fragment, and 36 were wild-type
littermates that acted as controls. At 2, 4, 9, 12, 14,
and 20 months of age, six Tg mice and six controls
were selected with equal numbers of male and fe-
male mice. All Tg mice used in this study were
hemizygous. 
Blood
Approximately 1 ml of blood was obtained by cardiac
puncture and drained into a 1-ml syringe primed with
25 l of ethylenediaminetetraacetic acid (EDTA) as
anticoagulant. The plasma was separated from the
formed elements by centrifugation and stored at
80C until used. Mouse brains were removed im-
mediately post mortem; the left cerebral hemispheres
were rapidly frozen in liquid nitrogen and stored at
80C and the right hemispheres were fixed in 4%
buffered paraformaldehyde.
Isolation and Quantification of A Peptides
Blood One hundred microliters of the rodent
plasma was diluted with 400 l of 98% formic acid
(Fluka Chemie AG, Buchs, Switzerland; glass dis-
tilled in our laboratory) and loaded onto a size-
exclusion Superose 12-column equilibrated with
80% glass distilled formic acid (GDFA). Plasma frac-
tionation was carried out on a Fast Performance Liq-
uid Chromatography apparatus (FPLC, Pharmacia
Biotech, Uppsala, Sweden) at a flow rate of 15 ml
per hr at room temperature (RT) and monitored at
280 nm. Fractions containing the 3- to 8-kDa pep-
tides were collected in polypropylene tubes, pooled,
and, after the addition of 5 l of 2% betaine, the
acid was eliminated by vacuum centrifugation. The
dried specimens were dissolved in 50 l of 80%
GDFA, then diluted with 250 l of 10 X TTBS (0.5 M
Tris-HCl, pH 8.0, 1.37 M NaCl, 27 mM KCl, 0.5%
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tissue. The pellets were homogenized in 1 ml of 2%
SDS in 20 mM Tris HCl, pH 8.0, and diluted 500 times
prior to application to the microtiter plates. The pro-
tein values were determined using Micro BCA Protein
Assay reagent kit (Pierce, Rockford, IL, USA).
Western blotting was used to determine the lev-
els of ApoE in the mouse brains. For this purpose we
used a goat anti-rat polyclonal antibody (see below).
This antibody was raised against rat ApoE purified
by the method of Holmquist and Carlson (16), its pu-
rity assessed by SDS-PAGE (17), and its specificity
confirmed by two-dimensional crossed immunoelec-
trophoresis (18). The Western blots were developed
with the Supersignal Chemiluminescent Subtrate
(Pierce) and the relative intensity of the bands mea-
sured on a scanning ChemiImager (Alpha Innotech
Corp., San Leandro, CA, USA).
Histochemical and Immunohistochemical Analyses The
right hemispheres from the Tg and non-Tg mice were
fixed for 48 hr in 4% paraformaldehyde in 0.1 M
phosphate buffer, pH 7.4, the tissue dehydrated with
alcohols and xylene, and embedded in paraffin wax.
Parasagittal 5-m thick sections of whole-hemisphere
sections were stained with modified Cambell-Switzer,
hematoxylin and eosin, thioflavine S, and by im-
munohistochemistry (19) for A, APP, and ApoE.
The primary antibodies used for A were 6E10
(Senetec, Maryland Heights, MO, USA) against the
A amino acid sequence 1–17, and R163 and R165
against the C-terminal portions of the A peptide
ending at amino acids 40 and 42 (20), respectively
(all three were used at a dilution of 1:1000). Frozen
sections (40-m thick) from an additional set of two
APP23 Tg animals and two non-Tg animals for each
age point in this study were used for immunohisto-
chemical staining for ApoE (anti-rat ApoE, kindly
provided by Dr. C. Bisgaier, Esperion Therapeutics,
Inc. and by Dr. P. Dolphin, Dalhousie University) at a
dilution of 1:100, and for heparan sulfate proteogly-
can (Chemicon, Temecula, CA, USA). For APP, the
22C11 antibody (Boehringer-Mannheim, Indianapo-
lis, IN, USA) against the N-terminus and the R37 an-
tibody (21) against the C-terminus were used at dilu-
tions of 1:50 and 1:5000, respectively. Sections
stained for A were pretreated for 5 min with 90%
formic acid while those stained for APP with the
22C11 antibody were pretreated for 1 min. Sections
stained for ApoE or APP with the R37 antibody
were first boiled for 10 min in 0.1 M sodium citrate
buffer, pH 7.4. Secondary antibodies and avidin-
biotin peroxidase complex were obtained from Vec-
tor (Burlingame, CA, USA). 3,3’-diaminobenzidine
(Sigma, St. Louis, MO, USA) with 1% nickel ammo-
nium sulfate was used as the chromogen. Some sec-
tions were counterstained with neutral red. Stained
sections were viewed with bright-field light mi-
croscopy (immunoperoxidase stains) or fluorescence
microscopy and confocal scanning laser microscopy
(thioflavine S-stained sections).
Tween 20). Volumes were then adjusted to 1 ml with
distilled water (DW), the pH adjusted to 7.4 with 
10 N NaOH using a pH meter equipped with a mi-
croelectrode and each specimen’s volume adjusted to
2.5 ml with DW. Samples were immediately sub-
mitted to A immunoassay: 50 l of the capture an-
tibody were plated either with the R163 antibody
raised against A residues 34–40 or with the R165
antibody raised against A residues 36–42, at con-
centrations of 10 g/ml in 10 mM sodium carbonate,
pH 9.6. After the addition of 100 l of blocking so-
lution (1% bovine serum albumin in TTBS), the
plates were incubated for 1 hr at RT. Either 100 l of
the test specimens or of the A40 or A42 standards
was added in triplicate and the plates incubated for
2 hr at RT on a rocking apparatus. Unbound materi-
als were removed by 4 TTBS automatic washes
(Tecan, Salzburg, Austria). After addition of 50 l of
the reporting antibody (4G8, raised against residues
17–24 of A) labeled with europium according to
the manufacturer’s specifications (Wallac Inc.,
Gaithersburg, MD, USA), the specimens were incu-
bated for 1 hr at RT and washed four times with
TTBS and three times with DW. Following addition
of 50 l of the Enhancement Solution (Wallac Inc.),
the plates were read in a fluorimeter (Wallac Inc.) at
an excitation of 340 nm and emission of 615 nm. The
concentrations of A in the samples were calculated
using the standard curves generated by each plate
(range 25–1000 pg/ml) as a frame of reference and
the final values adjusted to ng/ml considering the
experimental dilution factors.
Brain The amounts of water-soluble and water-
insoluble A peptides were related to the amount of
brain tissue (in mg) in the sample. Left cerebral hemi-
spheres from each mouse were minced and thor-
oughly disrupted with a Dounce homogenizer in 4 ml
of 50 mM Tris HCl, pH 7.4 buffer containing a mix-
ture of protease inhibitors (1 mM EDTA, 500 g/l
leupeptin, 700 g/l pepstatin, 350 mg/l phenyl-
methylsulfonyl fluoride, 100 mg/l o-phenanthroline,
and 100 mg/l benzamidine). The specimens were
centrifuged at 100,000 g in a Sorvall AH-650 rotor
at 4C for 1 hr. One hundred microliters of the super-
natant was applied to the microtiter plates for eu-
ropium immunoassay of water-soluble A peptides.
The insoluble pellets were homogenized in 1 ml of
2% SDS. Five hundred microliters of the homogenate
was mixed with 2 ml of 90% GDFA. Fifty microliters
of the acid lysate was neutralized as mentioned for
the plasma samples with the exception that the final
volume was brought up to 5 ml instead of 2.5 ml and
submitted to europium immunoassay. The final yields
of soluble and insoluble A were adjusted to g per g
of cerebral cortex.
Protein Quantification and Western Blotting
Protein determinations were performed on the aque-
ous supernatants and water-insoluble pellets of brain
Preparation of Whole-Mounts of Cerebral Vessels
The cerebrums from 20-month-old APP23 Tg mice
(n  4), and Tg2576 mice (n  4), were each sec-
tioned to separate the hemispheres and coronally cut
into two slices. The brain tissue was lysed with two
changes of 50 ml each of 2% SDS, 2 mM EDTA,
50mM Tris-HCl, pH 7.4. The tissue was very gently
stirred with a magnetic bar for a period of 36 hr, af-
ter which the vascular tufts were recovered by filtra-
tion through a 40-m nylon mesh fitted at the end of
a 2.5  10 cm Plexiglass cylinder. The nylon mesh
was immediately shaken into 50 ml of DW and the
vessels recovered by centrifugation at 1500  G for
15 min and washed once more with 50 ml of DW.
The resulting SDS-insoluble vascular extracellular
matrix and basal lamina with the attached amyloid
were spread out on a microscope slide, air dried at
60C for 3 hr, fixed with absolute ethanol for 30 min,
and rinsed with DW. The specimens were stained
with 0.2 m filtered 1% aqueous thioflavine S for
10 min, rinsed with 70% ethanol to remove un-
bound stain, and mounted under glass cover slips
with a gel medium.
Results
A Levels in Tg Mouse Plasma
There was an initial elevation of the plasma levels of
A40 and A42 from 2–9 months of age in the
APP23 Tg mice (Fig. 1AB). By 14 months, levels of
A had fallen, followed by a more moderate de-
crease by 20 months. A similar pattern was observed
in the non-Tg mouse population, with no statisti-
cally significant differences between the Tg and
non-Tg mice at any age for both A40 and A42
(Fig. 1C). At 9 months of age, the average values for
A40 and A42 in the Tg mice were 13 ng/ml and
19 ng/ml, respectively, which were close to the val-
ues for the non-Tg mice: 8 ng/ml and 16 ng/ml, re-
spectively. By 20 months of age, the plasma levels of
A40 and A42 in the Tg mice decreased to an aver-
age of 4 ng/ml and 3.8 ng/ml, respectively. In the
non-Tg mice, these values were lower: 1 ng/ml and
0.4 ng/ml, respectively (Fig. 1AB). However, the dif-
ferences between A40 levels in Tg and non-Tg
mice at 14 and 20 months were not significant
(p  0.051 and p  0.113, respectively).
A Levels in APP23 Tg Mouse Brains
The water-soluble fractions of A40 and A42 pep-
tides in APP23 Tg mouse brain were substantially and
constantly elevated at all ages when compared to the
levels in non-Tg mice (Fig. 2AB). Throughout the life
span of the Tg mice, the average levels of the A42
were higher than those of the A40 (34.4 g/g of cor-
tex versus 21.6 g/g). In contrast, the average values
for the rodent endogenous A40 and A42 were sim-
ilar in the non-Tg mice (3.9 g/g and 4.1 g/g, re-
spectively). At 2 months of age, the mean value for the
total soluble A in the brains of APP23 Tg mice was
612 Molecular Medicine, Volume 7, Number 9, September 2001
already four times greater than in the non-Tg mice. At
20 months of age, this difference was far more pro-
nounced, amounting to 33 times more total A in the
APP23 Tg mouse brains than in the non-Tg mice
(Fig. 2C). The relatively high values of total soluble
A at 2 months of age in the non-Tg mice may result
from the higher values of endogenous APP normally
observed during fetal development.
The water-insoluble fractions of A40 remained
at a basal level during the first 9 months after birth
in the brains of the APP23 Tg mice. This was fol-
lowed by a moderate increase until 14 months of
age and then a sharp elevation, to 680 g/g of cor-
tex, by 20 months (Fig. 3A). As expected, the levels
of endogenous insoluble A40 remained negligi-
ble throughout the life span of the non-Tg mice
(Fig. 3A). The levels of the water-insoluble A42 in
the APP23 Tg mice remained at a basal endogenous
level until the age of 14 months but then increased
Fig. 1. The levels of A in the plasma of the APP23 Tg
mice and control littermates. The measurements of these
peptides were made in the 3- to 8-kDa FPLC formic acid–
separated fractions at 2, 4, 9, 12, 14, and 20 months of age.
Solid and broken lines correspond to the Tg mice and control
mice, respectively. (A) A40. (B) A42. (C) the sum of A40
and A42. There were no significant differences between the
Tg and non-Tg mice.
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to other molecules which hinders immunoreactive
epitopes (22).
Levels of ApoE in Tg Mouse Brains
The values of ApoE in the brains of the APP23 Tg
mice were elevated relative to those obtained for the
non-Tg littermates (Fig. 4). This elevation was already
noticeable at 2 months of age and became significant
(p  0.020) in the Tg mice at 14 and 20 months of age
(Fig. 4).
Histologic Evolution of Amyloid Deposits
In the present study, deposits of A are first detected
by histology in the brain at 9 months of age in the
APP23 Tg mice. However, in a more extensive study,
amyloid deposits have been observed in animals as
young as 6.7 months of age (M. Staufenbiel, unpub-
lished observations). Such deposits are isolated or
widely scattered and reside mainly in the frontal
cortex (Fig. 5A). With increasing age, plaques increase
in number and in size, ranging up to 100 m in
diameter at 12 months (Fig. 5B), 180 m at 14 months
(Fig. 5C), and 200 m at 20 months (Fig. 5D).
by 20 months of age to about 60 g/g of cortex
(Fig. 3B). The average value for the non-Tg water-
insoluble A42 at 20 months of age was about 
24-fold lower (2.5 g/g of cortex) than in the APP23
Tg mice and considered to be the basal endogenous
value (Fig. 3B). 
When the levels of total soluble and insoluble
A40, as measured by europium immunoassay in
the APP23 Tg mice at 20 months of age, were added
and averaged, they amounted to 700 g/g of brain.
By the same age, the water-soluble and -insoluble
A42 yielded a mean value of 91.5 g/g of brain
(Figs. 2 and 3). There was a 7.7-fold greater abun-
dance of A40 over A42. The A40:A42 ratio
yielded by the acid extraction and subsequent chro-
matographic separation on a high performance liquid
chromatography reverse-phase 5RPC column, in a
previous study, however, showed only a 3- to 4-fold
greater abundance of A40 over A42 (13). The
discrepancy may be due to the use of 22-month-old
Tg mice in the previous study rather than the
younger 20-month-old Tg mice in the present study.
Furthermore, during the water extraction for the
EuIA some of the water-soluble A42 may be bound
Fig. 2. The levels of water-soluble A in APP23 Tg mice
and control littermate brains. The values were quantified by
europium immunoassay (EuIA) at the same ages as in Figure 1.
Solid lines, Tg mice; broken lines, control mice. (A) A40.
(B) A42. (C) The Summation of A40 and A42. Notice the
high levels of soluble A in the Tg mice, already evident at
2 months of age, relative to the control animals.
Fig. 3. The amounts of water-insoluble (SDS-GDFA
soluble) A in the APP23 Tg mice and non-Tg littermate
brains. The quantification was done by EuIA. The mice ages are
as in Figure 1. Solid lines, Tg mice; broken lines, control mice.
(A) A40. (B) A42. (C) The Sum of both A peptides. The
water-insoluble A40 begins to increase at 9 months of age,
reaching a substantial level by 20 months of age in the Tg mice.
The increase of the A42 is less pronounced than the A40 in
the Tg mice. The EuIA demonstrated a ratio of A40 to A42 
of 8.5:1.0.
Amyloid plaque core morphology also changes
with age. At 9 months, plaques consist mostly of
small dense bodies about 10–20 m in diameter
(Fig. 5E). Beginning at 12 months, star-like forms are
more common, with the arms of the stars composed of
radially arranged bundles of filaments (Fig. 5FG).
Cerebral amyloid angiopathy is first apparent at 
9 months of age in APP23 Tg mice and, like the A
plaques, becomes increasingly more common in older
animals. The thickness of the vascular amyloid coat
also increases in older animals (Fig. 5D), with some
vessels in 14- and 20-month-old animals exhibiting
prominent nodular deposits of amyloid (Fig. 5H). 
Staining patterns for A immunocytochemistry
vary in the 14- and 20-month-old APP23 Tg mouse
brains, depending on the antibody used. With the
6E10 antibody (Fig. 5I), plaque cores are intensely
stained and diffuse plaque-like staining is also pre-
sent, whereas the R163 antibody, against A40,
stains plaque cores intensely (Fig. 5J). The R165 an-
tibody, against A42, stained fewer plaque cores
with less intensity (Fig. 5K), but also resulted in
faint, focal staining of the neuropil, similar to diffuse
plaques seen in the human brains. Sections stained
with the antibody against ApoE showed intense
staining of plaques (Fig. 5L) from their first appear-
ance at 9 months of age. Control sections for the
ApoE antibody showed no staining when the pri-
mary antibody was omitted.
Immunocytochemistry for A and APP re-
vealed cytoplasmic staining of neurons. The 6E10
antibody against A showed intense, punctate stain-
ing within the cytoplasm of cortical (mostly layer
III, Fig. 5M) and hippocampal (CA1 region) pyra-
midal neurons (data not shown). This was first ap-
parent in 4-month-old animals when only a few
neurons per section were positive. Both the number
of positive neurons and the number and intensity of
intracellular punctae increased progressively with
age so that by 20 months positively stained neurons
were very common in the cortex. Such intracellular
staining was not present, however, with either the
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R163 (Fig. 5N) or R165 antibodies (data not shown)
against A ending at amino acid 40 or 42, respec-
tively. Staining with the antibodies 22C11 (Fig. 5O)
and R37 (Fig. 5P) against the N- and C-terminal
Fig. 4. The age-dependent relative levels of ApoE in the
cerebral cortex of the APP23 Tg mice and control litter-
mates measured by Western blot scanning densitometry.
Solid line, Tg mice; broken line, control mice.
Fig. 5. Photomicrographs of sections from APP23 Tg mice
brains. Images A through H were stained with thioflavine 
S and photographed using scanning laser confocal microscopy.
Images A through D illustrate the progressive accumulation of
cortical plaques with increasing age of the Tg animal, repre-
senting mice aged 9, 12, 14, and 20 months, respectively. Cali-
bration bar in A equals 500 m and serves for A–D. Images E
through G depict the typical increase in plaque size with in-
creasing age. Nine-, 12-, and 20-month-old animals are repre-
sented in E, F, and G, respectively. Image H shows two blood
vessels with intense thioflavine fluorescence of their walls as
well as exophytic growths of amyloid extending from the ves-
sel wall into the adjacent neuropil (arrow). Calibration bar in
E equals 50 m and serves for E–H. Photomicrographs
I through L show immunohistochemical staining of cortical
plaques with antibodies to A (I–K) and ApoE (L). Sections
I–K were counterstained with neutral red. Antibody 6E10,
against A1-17, stains both amyloid cores (I, lower arrow) and
diffuse-type plaques (I, upper arrow). The end-specific antibody
against A N-40, R163, stains cores intensely (J, arrow), but
does not stain diffuse plaques. The end-specific antibody 
directed at A N-42, R165, stains diffuse plaques (K, arrow),
but cores are stained poorly. Calibration bar in I equals 100 mm
and serves for I–K. Staining for ApoE revealed plaques in
numbers and morphology similar to that seen with thioflavine
S staining (L); calibration bar equals 75 m. Photomicrographs
M through P are included to show intracellular findings with
A and APP antibodies. The sections were counterstained for
cellular detail with neutral red. Antibody 6E10 reveals intracy-
toplasmic granules within large cortical pyramidal neurons
(M, arrows). Sections stained with the end-specific antibodies
R163 and R165, against carboxy terminal residues of A40 and
A42, respectively, did not show any intracellular reaction
product (staining with R165 is shown in N; staining with R163
was similar but is not shown). The sections seen in O and
P were stained with the 22C11 and R37 antibodies for the 
N- and C-termini of APP, respectively. Note the presence of
abundant intraneuronal granular reaction product. The calibra-
tion bar in M equals 15 mm and serves for M–P.
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with antibodies against the N- and C-termini of the
APP molecule confirmed the presence of large
amounts of full-length APP within these cells as early
as 4 months of age. Therefore, it appears that intracel-
lular A concentrations remain at low, histochemically
portions of APP, respectively, showed frequent and
profuse intraneuronal granular deposits within the
majority of cortical neurons.
None of the control sections were stained when
antibodies directed at A were used. This included
sections of brain from APP23 Tg mice stained as in-
dicated, but with omission of the primary antibody,
as well as sections from control, non-Tg littermates.
For APP immunocytochemistry, non-Tg littermates
showed light neuropil staining but lacked intraneu-
ronal staining. Control sections of brain prepared by
omitting the primary antibody were devoid of stain-
ing in Tg and non-Tg mouse brain.
Vascular Amyloid Load
Whole-mount preparations of the vascular tree from
22-month-old APP23 Tg mouse cerebrum, stained
with thioflavine S, revealed an extensive and heavy
load of amyloid in the walls of arteries and arterioles
in the brain parenchyma and in the leptomeninges
(Fig. 6B). Notably, this contrasted sharply with the
light and scanty load of vascular amyloid observed
in another strain of Tg rodent, the Tg2675 mice, also
at 22 months of age (Fig. 6A).
Discussion
We demonstrated that A40 and A42 levels in the
plasma of APP23 Tg mice were not significantly 
elevated above those of non-Tg mice at any point 
between 2 and 20 months of age. In contrast, water-
soluble and water-insoluble A in the brain were
elevated at 2 and 9 months, respectively, and in-
creased considerably with advancing age. The rise 
of A in the brain was accompanied by a signi-
ficant increase in ApoE, especially between 14 and
20 months of age. Histologic and immunocytochem-
ical analyses revealed morphologic changes in the
APP23 Tg mice that reflected the increased brain A
levels. Amyloid plaques increased progressively in
size and number from 9 to 20 months in the Tg mice,
and a substantial amount of A was deposited in
vessel walls as cerebral amyloid angiopathy was
histologically evident from the age of 9 months on-
ward. Immunocytochemistry showed colocalization
of ApoE, A40, and A42 in plaques, and also re-
vealed APP within neuronal cytoplasm of the APP23
Tg mice. 
The origin of A in AD is uncertain, even though
it is established that APP is the A precursor mole-
cule. Immunocytochemical analysis of APP23 Tg
mice revealed APP localization to neuronal cell bod-
ies. The possibility of A in the neurons was also
raised as they were stained with the 6E10 antibody,
which initially suggests the presence of intraneuronal
A. However, the lack of immunoreactivity with the
R163 and R165 antibodies, which specifically recog-
nize the A peptide C-termini, revealed that the 6E10
antibody is actually recognizing the A sequence
within the APP. The abundant intraneuronal staining
Fig. 6. Whole-mount preparations of Tg mice parenchy-
mal vessels stained with thioflavine S (yellow fluores-
cence). Top panel shows the Tg2576 mouse. Bottom panel
corresponds to the APP23 Tg mouse. There is an overwhelming
amount of vascular amyloid in the APP23 Tg mouse when 
compared to the Tg2576 mouse. The walls of most of the 
vessels are loaded with amyloid deposited along the 
perpendicularly oriented smooth muscle cells.
undetectable levels in these animals despite marked
overexpression of mutant APP. This finding may
have negative implications for recently emerging
hypotheses regarding the importance of intraneu-
ronal A in AD pathogenesis (22,23). Our immuno-
cytochemical studies have shown that a large part of
the neuronal cytoplasm is packed with APP that
could cause severe neuronal damage at the extreme
level expressed in the Tg mice. This may, per se, cre-
ate an abnormal condition, which may not be part of
the typical human AD pathogenesis.
Our experiments revealed that substantial differ-
ences exist in A accumulation kinetics and patterns
in different Tg mice strains that overproduce human
amyloid through enhanced expression of APP. The
amount of A in the brain and plasma of the
Tg2576 mice and control littermates was measured
at intervals between 2–20 months (15). The levels
of total A in plasma increased up to 12 months of
age in the Tg2576 mice, relative to controls, and
then fell to almost endogenous A levels (Fig. 7).
In contrast, while both water-soluble and water-
insoluble forms of A remained at basal levels in
the brain until 9 months of age, A increased expo-
nentially from 12–20 months of age Amyloid de-
posits in the brain parenchyma are first discernible
at 12 months of age in Tg2576 mice.
The dramatic differences between the APP23
and Tg2576 mice in the distribution of amyloid may
be due in part to the cDNA construct used. The
APP23 Tg mouse contains the APP751 cDNA con-
struct and includes the Kunitz protease inhibitor do-
main, which is absent in the APP695 cDNA construct
used in the Tg2576 Tg mice. Although both the Tg
mouse APPs carry the Swedish mutations to en-
hance the generation of A, the promoters are differ-
ent, with the Thy-1 in the APP23 Tg mouse and the
hamster prion in the Tg2576 Tg mouse. At least as
surprising as the difference between the two Tg
mice is the difference between the control strains.
This may be due to the different backgrounds of the
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two Tg mice. The APP23 Tg mice are in the C57BL/6J
(Black 6), which have been successfully back-crossed
with the same strain of mice, while the Tg2576 mice
were in the C57B6/SJL, which have been back-
crossed to the wild-type B6SJL mice from Jackson
Laboratories, Bar Harbor, Maine, USA.
The acute overexpression of proteins in trans-
genic mice may result in induction of compensatory
physiologic responses designed to eliminate the
abundant alien protein. Several mechanisms, alone
or in concert, include extracellular proteolysis, mi-
croglial, and/or astroglial phagocytosis with lysoso-
mal degradation, sequestration of A by binding
species such as ApoE or 2-macroglobulin, followed
by receptor-mediated endocytosis by brain or vascu-
lar cells expressing LDL or LRP receptors. Moreover,
a portion of the A could be eliminated through the
arachnoid granulations that remove cerebrospinal
fluid (CSF) into the venous circulation. 
In addition to direct mechanisms of A elimina-
tion, levels of brain protein may be controlled by al-
lowing transport into the blood. There are several
situations in which molecules are constantly pro-
duced within brain tissue but the absence of dis-
posal mechanisms leads to excessive accumulation
either within cells or extracellular spaces. Thus, dif-
ferent amyloid polypeptides, like A, cystatin, ABri,
and prions accumulate in the extracellular spaces of
the cerebral cortex. The pattern of A accumulation
in the walls of intracerebral and leptomeningeal ar-
teries in CAA suggests that it is deposited in the pe-
riarterial interstitial fluid drainage channels through
which, as suggested, A is normally eliminated
from the human brain (12,24). In CAA, A accumu-
lates in the walls of cortical capillaries, arterioles,
and small arteries and in leptomeningeal arteries to
such a degree that it is stained in histologic prepara-
tions. Biochemical studies, however, have detected
the presence of A in the walls of arteries as large as
the middle cerebral artery and basilar artery in
young adults in their third decade. Levels of A in
these arteries are significantly increased in AD, but
no A accumulation has been detected in extracra-
nial arteries (25). These observations support the
hypothesis that soluble A, possibly bound to ApoE,
is eliminated from the human brain along periarter-
ial interstitial fluid drainage pathways (26) that are
homologous with those described in rodents
(5,6,27). Soluble and particulate tracers injected into
the central gray matter of the rodent brain pass along
periarterial pathways into regional lymph nodes in
the neck (6,28,29). Experimental studies strongly
suggest that these pathways play a significant role in
B-cell immunity and T-cell immune reactions in the
rodent brain (6,28–30).
The pattern of A abundance in the Tg2576 mice
is in marked contrast to that in the APP23 Tg mice.
High levels of water-soluble A in the brains of
APP23 Tg mice from 2–20 months of age imply that
clearance of A may not be as efficient as in Tg2576
Fig. 7. Time-dependent comparison between the amount
of plasma levels of total A between two strains of Tg
mice (APP23 versus Tg2576) and their respective control
littermates. Tg, transgenic; C, non-transgenic controls. All
measurements were carried out by EuIA and adjusted to ng/ml
of plasma.
Y.-M. Kuo et al.: A Peptide Burden in APP23 Transgenic Mice 617
and in vessel walls. The incomplete separation of
interstitial fluid drainage pathways from the CSF
compartment in rodents (5,27) is reflected in the
very high levels of A amounting to approximately
40 ng/ml in the APP23 Tg mice CSF (31). These lev-
els are well above those seen in human AD CSF. Fur-
thermore, CSF A42 and A40 levels are decreased
in patients with AD relative to nondemented con-
trols. This probably reflects the greater separation of
Interstitial Fluid (ISF) drainage from the CSF in the
human brain compared with rodents (6). In humans,
the CSF and periarterial space are segregated by
the pia mater, whereas in rodents, the separation
between these compartments is more primitive and
the periarterial space directly communicates with the
CSF subarachnoidal space. This may be an addi-
tional factor in the higher incidence of A accumula-
tion in aged humans compared to aged animals.
The heterogeneity exhibited in almost every as-
pect of AD patients has complicated attempts to de-
fine risk factors and predict the course of the disease.
Consideration of the incomplete analogy between
AD and the Tg mouse models has led others to con-
clude that the more exact AD modeling may require
the “humanizing” of Tg systems (34). However, Tg
mice may be used to investigate separate facets of
AD, even if these models fail to completely mimic
the entire AD complex. We have confirmed that the
APP23 and the Tg2576 Tg mice can be used to in-
vestigate the critical elimination of A from the
brain. These transgenic model systems clearly will
enable productive evaluations of novel therapeutic
interventions directed toward decreasing amyloid
formation and deposition.
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